IRCT20151113025025N3招募中4 期
Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with coronavirus disease-2019 (COVID-19) referring to Sina and Imam-Khomeini Hospitals in 2020
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients who have suggestive signs of COVID-19 in their chest computed tomography scan, reported by a radiologist
- •Patients consuming angiotensin converting enzyme-inhibitors or angiotensin receptor blocker
排除标准
- •Uncontrolled hypertension with systolic blood pressure more than 180 or diastolic more than 120
- •Past history of congested heart failure or arrhythmia with various severity
- •Sensitivity to the newly-prescribed medications
- •History of severe asthma
- •History of known depression
- •Consuming medications with interactions such as lithium, antiepileptic drugs, chemotherapy
- •Patient unwillingness to enter the study
- •Patients whose prognosis is influenced by another disease
研究者
相似试验
Unknown
不适用
Effect of RAAS Blockade on Renal Outcome in CKD Stage 3-4 with Type 2 DM Patients: A Retrospective cohort studychronic kidney disease stage 3-4 type 2 diabetes mellitusdiabetes mellituschronic kidney diseaseTCTR20230512002Faculty of Pharmaceutical Sciences, Burapha University13,488
尚未招募
不适用
Prospective randomized trial of angiotensin receptor neprilysin inhibitor addition after ablation for atrial fibrillation with hypertensioAtrial Fibrillation with hypertensionJPRN-UMIN000046613Cardiology University Northern Yokohama Hospital200
进行中（未招募）
1 期
BLOCKADE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN PATIENTS WITH ARVD.BRAVEArrhythmogenic right ventricular dysplasiaMedDRA version: 20.1Level: PTClassification code: 10058093Term: Arrhythmogenic right ventricular dysplasia Class: 100000004850CTIS2023-505048-20-00Hospices Civils De Lyon120
进行中（未招募）
1 期
Renin angiotensin Aldosterone (RAAS) axis, endothelial function and hypertension: diagnostic strategies and therapeutic role of potassium supplementatioWe are seeking to determine the effects of potassium supplementation vs placebo for 6 weeks on the renin-angiotensin-aldosterone axis and also endothelial function in subjects with 10-20% 10 year cardiovascular risk.EUCTR2008-001738-29-GBBelfast Health and Social Care Trust40
招募中
不适用
Impact of Renin-Angiotensin-Aldosterone-System Inhibition on Advanced Chronic Kidney Disease progression – a Retrospective Observational StudyN18.4Chronic kidney disease, stage 4DRKS00034706niversitätsklinikum Freiburg6,000